Flexion Therapeutics, Inc. Discuss Recent FDA Approval of ZILRETTAT Call
Llamada en conferencia Flexion Therapeutics Inc
Flexion Therapeutics Inc Conference call will be held on 09-oct-2017. During the earnings conference call's session Flexion Therapeutics Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Flexion Therapeutics Inc for this information
Schedule an online conference with QCONF conference service and get 5 free calls with online conferencing.
Unless the content requires otherwise, references to "Flexion," "Company," "we," "our," and "us," in this Annual Report refer to Flexion Therapeutics, Inc. and our subsidiary, Flexion Securities Corporation, Inc. Overview We are a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, or OA, a type of degenerative arthritis. Our portfolio of product candidates addresses the OA pain treatment spectrum, from moderate to severe pain, and provides us with multiple opportunities to achieve our goal of commercializing novel, targeted, locally administered therapies. Our lead product candidate, Zilretta, is a late-stage, injectable, sustained-release, intra-articular, or IA, meaning "in the joint," steroid that we are developing as a treatment for patients with moderate to severe OA pain.Leer más Llamada en conferencia